• Herantis Pharma highlighted newly published evidence supporting its HER-096 Phase 2 trial design, showing smartphone assessments detect Parkinson’s progression more sensitively.
• The trial will assess efficacy in approximately 100 recently diagnosed patients not receiving symptomatic medication, using smartphone-based motor assessments.
• Placebo-controlled treatment will increase from six to nine months, followed by six months of HER-096 treatment for all participants.
• The extended treatment period will not increase estimated study costs or overall funding requirements through the Phase 2 readout.
• Trial application submission is targeted for Q4 2026, with first dosing expected in H1 2027, subject to financing and regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Herantis Pharma Oyj published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.